• Login
    ARAN - Access to Research at NUI Galway
    View Item 
    •   ARAN Home
    • Support Services
    • Externally hosted open access publications with NUI Galway authors (2)
    • View Item
    •   ARAN Home
    • Support Services
    • Externally hosted open access publications with NUI Galway authors (2)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ARANCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypesThis CollectionBy Issue DateAuthorsTitlesSubjectsTypes

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Help

    How to submit and FAQs

    Gonadotropin-releasing hormone agonist-induced pituitary apoplexy

    Thumbnail
    View/Open
    Full Text
    Date
    2016-06-08
    Author
    Keane, Fergus
    Egan, Aoife M
    Navin, Patrick
    Brett, Francesca
    Dennedy, Michael C
    Metadata
    Show full item record
    Usage
    This item's downloads: 0 (view details)
    
    Recommended Citation
    Keane, Fergus; Egan, Aoife M; Navin, Patrick; Brett, Francesca; Dennedy, Michael C (2016). Gonadotropin-releasing hormone agonist-induced pituitary apoplexy. Endocrinology, Diabetes & Metabolism Case Reports ,
    Published Version
    http://doi.org/10.1530/edm-16-0021
    Abstract
    Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Drug-induced pituitary apoplexy is a rare but important consideration when evaluating patients with this presentation. We describe an unusual case of a patient with a known pituitary macroadenoma presenting with acute-onset third nerve palsy and headache secondary to tumour enlargement and apoplexy. This followed gonadotropin-releasing hormone (GNRH) agonist therapy used to treat metastatic prostate carcinoma. Following acute management, the patient underwent transphenoidal debulking of his pituitary gland with resolution of his third nerve palsy. Subsequent retrospective data interpretation revealed that this had been a secretory gonadotropinoma and GNRH agonist therapy resulted in raised gonadotropins and testosterone. Hence, further management of his prostate carcinoma required GNRH antagonist therapy and external beam radiotherapy. This case demonstrates an uncommon complication of GNRH agonist therapy in the setting of a pituitary macroadenoma. It also highlights the importance of careful, serial data interpretation in patients with pituitary adenomas. Finally, this case presents a unique insight into the challenges of managing a hormonal-dependent prostate cancer in a patient with a secretory pituitary tumour.
    URI
    http://hdl.handle.net/10379/12176
    Collections
    • Externally hosted open access publications with NUI Galway authors (2)
    • Copyright @ NUI Galway
    • Library
    • NUI Galway